Pharmacological prevention of restenosis after percutaneous transluminal coronary angioplasty [PTCA]: overview and methodological considerations
- 1 January 1993
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patientsJournal of the American College of Cardiology, 1991
- Restenosis after directional coronary atherectomy: Differences between primary atheromatoes and restenosls lesions and influence of subintimal tissue resectionJournal of the American College of Cardiology, 1990
- Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries.Circulation, 1990
- Coronary atherectomy. Clinical, angiographic, and histological findings and observations regarding potential mechanisms.Circulation, 1990
- Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: A histopathologic studyJournal of the American College of Cardiology, 1990
- Platelet inhibitor agents in cardiovascular disease: An updateJournal of the American College of Cardiology, 1989
- “Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters”—the future treatment of atherosclerotic coronary disease? A clinical-morphologic assessmentJournal of the American College of Cardiology, 1989
- Re-Stenosis after Successful Coronary AngioplastyNew England Journal of Medicine, 1988
- Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplastyJournal of the American College of Cardiology, 1985
- Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration.Heart, 1983